Sunitinib, a new vascular endothelial growth factor receptor inhibitor, has demonstrated high
activity in renal cell carcinoma (RCC) and is now widely used for patients with metastatic …

The introduction of targeted therapy represents a major advance in the treatment of tumor
progression. Targeted agents are a novel therapeutic approach developed to disrupt …

Objective The effects of sunitinib in a broad patient population, especially those of Asian
ethnicity, have been rarely investigated. Here, we assessed the efficacy and safety of …

Clear-cell renal cell carcinoma (ccRCC) is a histological subtype of renal cell carcinoma-the
most prevalent adult kidney cancer. Causes of ccRCC are not completely understood and …

Metastatic renal cell carcinomas (mRCC) are highly vascularized tumors that are a paradigm
for the treatment with antiangiogenesis drugs targeting the vascular endothelial growth …

Purpose To assess the safety and efficacy of sunitinib in patients with bevacizumab-
refractory metastatic renal cell carcinoma (mRCC) and explore biomarkers for sunitinib …

Purpose Concurrent inhibition of multiple oncogenic signaling pathways might improve the
efficacy of anticancer agents and abrogate resistance mechanisms. This phase I study …

Background Sunitinib resistance can be classified into primary and secondary resistance.
While accumulating research has indicated several underlying factors contributing to …

Purpose: Resistance to antiangiogenic tyrosine kinase inhibitors such as sunitinib is an
important clinical problem, but its underlying mechanisms are largely unknown. We …

Sunitinib, a multitargeted receptor tyrosine kinase inhibitor including vascular endothelial
growth factor, has been widely used as a first‐line treatment against metastatic renal cell …